I always assumed that randomization took into account the patient's history and other medications/illnesses to ensure each arm was roughly as similar as possible. So in our trial's case if we were to randomize a handful of patients, we would want to ensure that for every patient on Remdesivir that is randomized to Leronlimab there should be another patient that is "similar" who is randomized to placebo. So that way you don't have an entire control arm that was devoid of Remdesivir use while the entire placebo arm had it on board. Or one arm full of 65+ and the other arm consisting of mostly under 65 year olds. Basically just an effort to level the playing field that still has some randomness to it but is also still strategic in design. This is all just something that's been gnawing at the back of my head from my pharma days. I haven't looked into it. Perhaps you or someone else might know for sure how that part of the process is actually handled?